PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 4.8% – What’s Next?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares fell 4.8% on Wednesday . The stock traded as low as $21.82 and last traded at $21.7910. 45,548 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,611,013 shares. The stock had previously closed at $22.89.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: CEO Larry Wood purchased 23,900 PRCT shares at an average price of $20.85, investing approximately $498,315. The open-market purchase may signal that management views the stock as undervalued. SEC Form 4 filing
• Neutral Sentiment: Several firms reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status in the proposed class action. The notices are largely procedural and do not constitute new company disclosures, although they keep the litigation in focus. The covered purchase period is February 28, 2024, through February 25, 2026. Class action deadline notice
• Negative Sentiment: The lawsuit alleges that PROCEPT and certain executives made false or misleading statements regarding handpiece demand and sales, procedure volumes and excess customer inventory created by repeated late-quarter bulk discounts. Potential consequences include legal costs, reputational damage and greater uncertainty about the company’s sales trajectory. Former Chief Commercial Officer Hisham Shiblaq was also identified as a secondary defendant. Levi and Korsinsky lawsuit notice
• Negative Sentiment: Recent quarterly results showed mixed fundamentals: revenue rose 19.3% year over year to $94.5 million and exceeded estimates, but the company posted a $0.47 per-share loss, slightly worse than expected. PROCEPT remains unprofitable, with analysts forecasting a full-year loss. Q2 2026 earnings call transcript

Analyst Ratings Changes

PRCT has been the topic of a number of research analyst reports. Robert W. Baird set a $20.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. UBS Group cut PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research note on Tuesday, July 28th. William Blair downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Finally, Citigroup lowered PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.00.

PROCEPT BioRobotics Stock Performance

The company’s fifty day moving average price is $21.39 and its 200 day moving average price is $24.63. The company has a market cap of $1.23 billion, a PE ratio of -11.07 and a beta of 0.89. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. During the same quarter last year, the firm posted ($0.35) earnings per share. The firm’s revenue for the quarter was up 19.3% compared to the same quarter last year. On average, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Larry L. Wood acquired 23,900 shares of PROCEPT BioRobotics stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at $498,315. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 1,000 shares of company stock valued at $28,480 over the last 90 days. 4.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors have recently added to or reduced their stakes in PRCT. BlackRock Inc. bought a new stake in shares of PROCEPT BioRobotics in the 2nd quarter worth approximately $109,961,000. Prosight Management LP grew its holdings in PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock valued at $43,415,000 after purchasing an additional 1,303,009 shares during the period. Alliancebernstein L.P. increased its position in PROCEPT BioRobotics by 58.6% in the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock worth $122,052,000 after buying an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after buying an additional 1,218,815 shares during the last quarter. Finally, William Blair Investment Management LLC bought a new stake in shares of PROCEPT BioRobotics in the second quarter valued at $16,020,000. Institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.